| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| VT-1021 | VT-1021 | Phase 3 Clinical | Vigeo Therapeutics Inc | Solid tumours; Glioblastoma | Details |
| TAX-2 | TAX-2; AP-01; AP-02 | Phase 2 Clinical | Centre National De La Recherche Scientifique (Cnrs), University of Reims | Solid tumours; Thrombosis | Details |




